Once again a trial that didn't meet the primary endpoint. Yes the combination of Remestemcel-L + dexamethasone in patients under 65 looks promising, but this is an exploratory result only. MSB (or the NIH) is going to have to run another double blind trial before the FDA is going to approve anything.
One positive piece of news is this does suggest that Remestemcel-L + dexamethasone is at least additive which is encouraging for the next AGvHD trial.
Ann: COVID ARDS Trial Topline 60-Day Results, page-97
-
- There are more pages in this discussion • 1,532 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.49 |
Change
0.140(10.4%) |
Mkt cap ! $1.701B | |||
| Open | High | Low | Value | Volume |
| $1.37 | $1.54 | $1.37 | $23.10M | 15.82M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 24758 | $1.49 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.49 | 73626 | 3 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |